Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Noxopharm Ltd. ( (AU:NOX) ) has shared an update.
Noxopharm Ltd has applied for quotation on the ASX of 15 million new ordinary fully paid shares issued on 27 February 2026. The shares were created in connection with a new financing facility, with the share issue and execution of the related facility agreement completed on the same day, indicating the company is bolstering its funding capacity through equity-linked arrangements.
The additional securities expand Noxopharm’s quoted share base and provide access to capital that can be deployed into its ongoing operations and development programs. This move may dilute existing shareholders but is likely aimed at strengthening the company’s financial position and supporting its strategic and research activities in the biopharmaceutical market.
The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.
More about Noxopharm Ltd.
Noxopharm Ltd is an Australia-based biotechnology company listed on the ASX under the code NOX. The company operates in the biopharmaceutical sector, focusing on the development of therapeutics, with its activities funded in part through capital market financing arrangements.
Average Trading Volume: 172,577
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$20.46M
For an in-depth examination of NOX stock, go to TipRanks’ Overview page.